CHF Solutions Announces the Launch of Pediatric Ultrafiltration Therapy Using the Aquadex SmartFlow System at Children’s Ho...
June 04 2020 - 08:00AM
CHF Solutions (Nasdaq: CHFS) today announced Children’s Hospital of
The King’s Daughters (CHKD) in Norfolk, Virginia has initiated
ultrafiltration therapy using the Aquadex SmartFlow™ system.
“Following FDA clearance and the launch of the
Aquadex SmartFlow system in the first quarter, we continue to see
strong interest from pediatric hospitals,” said John Erb, chairman
and CEO of CHF Solutions. “We are proud to work with the
medical team at Children’s Hospital of The King’s Daughters to
bring this simple, gentle and smart therapy to its patients
suffering from fluid overload.”
“We will use this ultrafiltration therapy to
accommodate the needs of children that require fluid removal
without the added risk of hemodialysis and to meet the needs of ICU
patients with heart disease that don’t respond to diuretics,” said
Dr. Irene Restaino, M.D., Medical Director of Nephrology at
CHKD.
About Children’s Hospital of The King’s
Daughters
CHKD is the only freestanding children’s hospital
in Virginia and serves the medical and surgical needs of children
throughout greater Hampton Roads, the Eastern Shore of Virginia,
and northeastern North Carolina. The not-for-profit CHKD
Health System operates primary care pediatric practices, surgical
practices, multi-service health centers, urgent care centers and
satellite offices throughout its service region.
About CHF Solutions
CHF Solutions, Inc. (CHFS) is a medical device
company dedicated to changing the lives of patients suffering from
fluid overload through science, collaboration, and innovation.
The company is focused on developing, manufacturing and
commercializing the Aquadex SmartFlow™ system for ultrafiltration
therapy. CHF Solutions is headquartered in Minneapolis, Minn., with
wholly-owned subsidiaries in Australia and Ireland. The
company has been listed on the Nasdaq Capital Market since February
2012.
About the Aquadex SmartFlow
System
The Aquadex SmartFlow system delivers clinically
proven therapy using a simple, flexible and smart method of
removing excess fluid from patients suffering from hypervolemia
(fluid overload). The Aquadex SmartFlow system is indicated
for temporary (up to 8 hours) or extended (longer than 8 hours in
patients who require hospitalization) use in adult and pediatric
patients weighing 20 kg or more whose fluid overload is
unresponsive to medical management, including diuretics. All
treatments must be administered by a health care provider, within
an outpatient or inpatient clinical setting, under physician
prescription, both having received training in extracorporeal
therapies.
Forward-Looking Statements
Certain statements in this release may be
considered forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including without
limitation, statements about the increased interest in therapy
using the Aquadex SmartFlow system with pediatric patients.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future
events to differ materially from the forward-looking statements in
this release, including, without limitation, those risk associated
with our expectations regarding the potential impacts of the
COVID-19 pandemic on our business operations, our ability to
execute on our commercial strategy, the possibility that we may be
unable to raise sufficient funds necessary for our anticipated
operations, our post-market clinical data collection activities,
benefits of our products to patients, our expectations with respect
to product development and commercialization efforts, our ability
to increase market and physician acceptance of our products,
potentially competitive product offerings, intellectual property
protection, our ability to integrate acquired businesses, our
expectations regarding anticipated synergies with and benefits from
acquired businesses, and other risks and uncertainties described in
our filings with the SEC. Forward-looking statements speak only as
of the date when made. CHF Solutions does not assume any
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Feb 2024 to Mar 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2023 to Mar 2024